![adctherapeutics may14][1]
Epalinges, Switzerland-based ADC Therapeutics is scheduled to list its stock on the NYSE, under the symbol ‘ADCT’, on May 14, 2020. This is the second attempt of the company to go public. ADC Therapeutics, which is a spinoff from Spirogen Ltd., had withdrawn its IPO filing in September 2019, citing adverse market conditions.
[Read More][2]